Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 166 900 KRW 3.02% Market Closed
Market Cap: 2T KRW

Green Cross Corp
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Green Cross Corp
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Free Cash Flow
-â‚©98.1B
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
-3%
Celltrion Inc
KRX:068270
Free Cash Flow
â‚©493.9B
CAGR 3-Years
N/A
CAGR 5-Years
86%
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Free Cash Flow
-â‚©300.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Free Cash Flow
â‚©109.4B
CAGR 3-Years
38%
CAGR 5-Years
51%
CAGR 10-Years
49%
Alteogen Inc
KOSDAQ:196170
Free Cash Flow
â‚©66.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
ABL Bio Inc
KOSDAQ:298380
Free Cash Flow
-â‚©44.8B
CAGR 3-Years
-1%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
252 272.64 KRW
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Free Cash Flow?
Free Cash Flow
-98.1B KRW

Based on the financial report for Jun 30, 2025, Green Cross Corp's Free Cash Flow amounts to -98.1B KRW.

What is Green Cross Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-3%

Over the last year, the Free Cash Flow growth was 30%.

Back to Top